Compare Personalis Inc. Common Stock (PSNL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Personalis Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? Personalis Inc. Common Stock trades at $16.07 (market cap $1.69B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 6.6× Personalis Inc. Common Stock's market cap, and Personalis Inc. Common Stock is more actively traded (3,817,236 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Personalis Inc. Common Stock for 0 Days and Repligen Corporation Common Stock for 0 Days on average.
| PSNL | RGEN | |
|---|---|---|
Market Cap | $1.69B | $11.14B |
Volume | 3,817,236 | 1,259,263 |
Sector | Health | Health |
52-Week High | $18.38 | $194.57 |
52-Week Low | $5.04 | $102.87 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $1.52B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Personalis Inc. Common Stock
Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
